CureTech Ltd. has applied to the US Food and Drug Administration (FDA) to conduct a Phase II clinical trial of its CT-011 treatment for metastic melanoma.
The open label trial will include 100 patients at medical centers in the US, Europe, and Israel. CureTech plans to begin the trial by the end of the year. (In an open label trial, both the researchers and participants know which treatment is being administered.)
CureTech is concurrently analyzing the results of the CT-011 Phase II clinical trial on diffuse large B-Cell lymphoma, and is continuing the Phase II trials on colon and blood cancers.
The US National Cancer Institute rates CT-011's operating mechanism as the second most important of 140 possible mechanisms in terms of potential treatments.
Clal Biotechnology Industries Ltd. (TASE: CBI), the life sciences arm of Nochi Dankner-controlled IDB Holding Corp. Ltd. (TASE:IDBH), owns 37% of CureTech, and Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA; TASE: TEVA) has invested in the company.
Published by Globes [online], Israel business news - www.globes-online.com - on May 3, 2011
© Copyright of Globes Publisher Itonut (1983) Ltd. 2011